TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: Brentuximab Vedotin, an antibody drug conjugate to CD30, has an ORR of 86% in relapsed and refractory anaplastic large cell lymphoma (ALCL) but is not applicable to most other peripheral T cell lymphomas (PTCL) subtypes, which do not express CD30 [4].